One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Entering the Era of Multidimensional Prognostication for Personalized Risk Assessment in Stage III Colon Cancer.
doi : 10.1200/JCO-25-00205
Volume 43(15) pgs. 1751-1847 May 20, 2025
Letetresgene Autoleucel: A Milestone in Treatment of Myxoid/Round Cell Liposarcoma.
doi : 10.1200/JCO-25-00055
Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial.
doi : 10.1200/JCO-24-02076
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials.
doi : 10.1200/JCO.23.02262
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
doi : 10.1200/JCO-24-01466
Trend and Provider- and Organizational-Level Factors Associated With Early Palliative Care Billing Among Patients Diagnosed With Distant-Stage Cancers in 2010-2019 in the United States.
doi : 10.1200/JCO-24-01935
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
doi : 10.1200/JCO.24.00727
High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.
doi : 10.1200/JCO-24-01851
Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
doi : 10.1200/JCO-24-01989
Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment.
doi : 10.1200/JCO-25-00457
Treatment Intensification Based on Residual Disease in Elderly Patients With AML.
doi : 10.1200/JCO-24-02645
Reply to: Treatment Intensification Based on Residual Disease in Elderly Patients With AML.
doi : 10.1200/JCO-25-00198
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
doi : 10.1200/JCO-24-02733
Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
doi : 10.1200/JCO-25-00308
Erratum: Fertility Preservation in People With Cancer: ASCO Guideline Update.
doi : 10.1200/JCO-25-00662
Erratum: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
doi : 10.1200/JCO-25-00779
